Form 8-K · Current report
Illinois Tool Works 8-K, filed Jul 28, 2026
- Filed
- CIK
- 0000049826
- Accession no.
- 0000049826-26-000047
Summary
Illinois Tool Works reported second-quarter 2026 revenue of $4.30 billion, up 6.1% with organic growth of 4.5%, operating income of $1.15 billion, and GAAP earnings per share of $2.84, and raised its full-year 2026 guidance. CEO Christopher A. O'Herlihy attributed the results to double-digit organic growth in Welding and Test & Measurement and Electronics and said ITW is raising both top- and bottom-line guidance.
Key points
- Second-quarter revenue was $4.30 billion, up 6.1% from a year earlier, with organic growth of 4.5%.
- Operating income was $1.15 billion, up 7.4%, and operating margin was 26.7%.
- GAAP EPS was $2.84, up 10.1%; free cash flow was $631 million, up 41%.
- ITW raised full-year 2026 GAAP EPS guidance to a range of $11.35 to $11.55 and organic revenue growth guidance to 3% to 4%.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On July 28, 2026, Illinois Tool Works Inc. (the "Company") announced its 2026 second quarter results of operations in the press release furnished as Exhibit 99.1. Non-GAAP Financial Measures The Company uses free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. The Company believes this non-GAAP financial measure, along with free cash flow to net income conversion rate, are useful to investors in evaluating the Company’s financial performance and measures the Company's ability to generate cash internally to fund Company initiatives. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.